Alignment Healthcare, Inc. $ALHC Shares Sold by First Light Asset Management LLC

First Light Asset Management LLC lowered its stake in shares of Alignment Healthcare, Inc. (NASDAQ:ALHC) by 47.1% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 203,138 shares of the company’s stock after selling 180,525 shares during the period. First Light Asset Management LLC owned about 0.10% of Alignment Healthcare worth $3,545,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Wellington Management Group LLP raised its position in Alignment Healthcare by 167.3% during the third quarter. Wellington Management Group LLP now owns 11,089,727 shares of the company’s stock valued at $193,516,000 after acquiring an additional 6,940,277 shares in the last quarter. Invesco Ltd. boosted its position in Alignment Healthcare by 122.3% in the 2nd quarter. Invesco Ltd. now owns 4,170,529 shares of the company’s stock worth $58,387,000 after purchasing an additional 2,294,739 shares in the last quarter. Marshall Wace LLP grew its stake in shares of Alignment Healthcare by 173.3% during the 2nd quarter. Marshall Wace LLP now owns 2,039,714 shares of the company’s stock worth $28,556,000 after purchasing an additional 1,293,416 shares during the period. Voya Investment Management LLC grew its stake in shares of Alignment Healthcare by 61.0% during the 3rd quarter. Voya Investment Management LLC now owns 3,196,297 shares of the company’s stock worth $55,775,000 after purchasing an additional 1,210,930 shares during the period. Finally, Integral Health Asset Management LLC increased its holdings in shares of Alignment Healthcare by 300.0% during the 3rd quarter. Integral Health Asset Management LLC now owns 1,600,000 shares of the company’s stock valued at $27,920,000 after purchasing an additional 1,200,000 shares in the last quarter. Institutional investors and hedge funds own 86.19% of the company’s stock.

Alignment Healthcare Trading Down 0.8%

ALHC stock opened at $16.99 on Monday. Alignment Healthcare, Inc. has a 12-month low of $11.63 and a 12-month high of $23.87. The business’s 50-day moving average is $20.76 and its 200 day moving average is $18.77. The company has a current ratio of 1.71, a quick ratio of 1.71 and a debt-to-equity ratio of 1.80. The stock has a market cap of $3.47 billion, a price-to-earnings ratio of -1,697.30, a PEG ratio of 2.49 and a beta of 1.19.

Alignment Healthcare (NASDAQ:ALHC) last announced its earnings results on Thursday, February 26th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.10. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. Alignment Healthcare had a negative return on equity of 0.49% and a negative net margin of 0.02%.The business’s revenue was up 44.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.16) earnings per share. On average, sell-side analysts anticipate that Alignment Healthcare, Inc. will post -0.69 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on ALHC shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alignment Healthcare in a research note on Wednesday, January 21st. Piper Sandler raised their price target on shares of Alignment Healthcare from $20.00 to $30.00 and gave the company an “overweight” rating in a research report on Tuesday, January 6th. TD Cowen lifted their price objective on shares of Alignment Healthcare from $18.50 to $25.00 and gave the company a “buy” rating in a report on Friday, January 16th. JPMorgan Chase & Co. upped their price objective on shares of Alignment Healthcare from $23.00 to $26.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Finally, KeyCorp reissued an “overweight” rating and set a $28.00 target price on shares of Alignment Healthcare in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $24.56.

Insider Transactions at Alignment Healthcare

In related news, President Dawn Christine Maroney sold 29,113 shares of the stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $17.45, for a total value of $508,021.85. Following the completion of the transaction, the president directly owned 963,702 shares of the company’s stock, valued at approximately $16,816,599.90. This represents a 2.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Robert L. Scavo sold 4,044 shares of the firm’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $17.45, for a total value of $70,567.80. Following the completion of the transaction, the insider owned 498,970 shares in the company, valued at $8,707,026.50. The trade was a 0.80% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 2,066,821 shares of company stock valued at $40,250,493 over the last ninety days. Company insiders own 6.60% of the company’s stock.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.